{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:04:25Z","timestamp":1790852665039,"version":"4.1.0"},"reference-count":92,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1097\/jcp.0b013e318059361a","type":"journal-article","created":{"date-parts":[[2007,5,9]],"date-time":"2007-05-09T08:05:46Z","timestamp":1178697946000},"page":"263-272","source":"Crossref","is-referenced-by-count":180,"title":["The Role of Anticonvulsant Drugs in Anxiety Disorders"],"prefix":"10.1097","volume":"27","author":[{"given":"Marco","family":"Mula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni B.","family":"Cassano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210128","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.4088\/JCP.v64n1201","article-title":"Brainstorms: symptoms and circuits, part 2: anxiety disorders.","volume":"64","author":"Stahl","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R2-6-20210128","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nm1074","article-title":"The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions.","volume":"10","author":"Rogawski","year":"2004","journal-title":"Nat Med"},{"key":"R3-6-20210128","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1016\/0006-2952(88)90684-3","article-title":"The GABA-A receptor-gated ion channel: biochemical and pharmacological studies of structure and function.","volume":"27","author":"Schwartz","year":"1988","journal-title":"Biochem Pharmacol"},{"key":"R4-6-20210128","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archpsyc.55.8.715","article-title":"Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study.","volume":"55","author":"Malizia","year":"1998","journal-title":"Arch Gen Psychiatry"},{"issue":"suppl 10","key":"R5-6-20210128","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1111\/j.1528-1157.1999.tb00887.x","article-title":"Psychiatric syndromes related to antiepileptic drugs.","volume":"40","author":"Schmitz","year":"1999","journal-title":"Epilepsia"},{"key":"R6-6-20210128","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1212\/WNL.53.7.1503","article-title":"Psychiatric adverse events during vigabatrin therapy.","volume":"53","author":"Levinson","year":"1999","journal-title":"Neurology"},{"key":"R7-6-20210128","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1046\/j.1528-1157.2003.05402.x","article-title":"Topiramate and psychiatric adverse events in patients with epilepsy.","volume":"44","author":"Mula","year":"2003","journal-title":"Epilepsia"},{"key":"R8-6-20210128","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF02253599","article-title":"Effect of peripheral administration of cinnarizine and verapamil on the abstinence syndrome in diazepam-dependent rats.","volume":"106","author":"Chugh","year":"1992","journal-title":"Psychopharmacology"},{"key":"R9-6-20210128","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.2042-7158.1997.tb06805.x","article-title":"Influence of certain calcium-channel blockers on some aspects of lorazepam-dependence in mice.","volume":"49","author":"Saad","year":"1997","journal-title":"J Pharm Pharmacol"},{"issue":"suppl 1","key":"R10-6-20210128","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1177\/070674372001460101004","article-title":"Clinical guidelines for the treatment of depressive disorders: IV medication and other biological treatments.","volume":"46","author":"Kennedy","year":"2001","journal-title":"Can J Psychiatry"},{"key":"R11-6-20210128","first-page":"64","article-title":"Antiepileptic drugs: the bridge between neurology and psychiatry.","volume":"1","author":"Mula","year":"2005","journal-title":"Asp Aff"},{"key":"R12-6-20210128","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1046\/j.1472-8206.2001.00055.x","article-title":"The clinical pharmacology and therapeutic use of the new antiepileptic drugs.","volume":"15","author":"Perucca","year":"2001","journal-title":"Fundam Clin Pharmacol"},{"issue":"suppl 2","key":"R13-6-20210128","first-page":"S53","article-title":"Positive and negative psychotropic effects of antiepileptic drugs in patients with seizure disorders.","volume":"53","author":"Ketter","year":"1999","journal-title":"Neurology"},{"key":"R14-6-20210128","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1176\/ajp.143.1.113","article-title":"Posttraumatic stress disorder and partial complex seizures.","volume":"143","author":"Stewart","year":"1986","journal-title":"Am J Psychiatry"},{"key":"R15-6-20210128","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/jts.2490090413","article-title":"The use of anticonvulsants in posttraumatic stress disorder: case study and overview.","volume":"9","author":"Ford","year":"1996","journal-title":"J Trauma Stress"},{"key":"R16-6-20210128","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1176\/jnp.11.1.97","article-title":"Carbamazepine in the treatment of Lyme disease-induced hyperacusis.","volume":"11","author":"Nields","year":"1999","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R17-6-20210128","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0033-3182(86)72590-5","article-title":"Preliminary study of carbamazepine in post-traumatic stress disorder.","volume":"27","author":"Lipper","year":"1986","journal-title":"Psychosomatics"},{"key":"R18-6-20210128","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/0006-3223(88)90011-X","article-title":"Posttraumatic stress disorder in Vietnam veterans clinical and EEG findings: possible therapeutic effect effects of carbamazepine.","volume":"23","author":"Wolf","year":"1988","journal-title":"Biol Psychiatry"},{"key":"R19-6-20210128","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/00004583-199506000-00008","article-title":"Carbamazepine for PTSD.","volume":"34","author":"Loof","year":"1995","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R20-6-20210128","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1176\/ajp.146.4.558b","article-title":"Carbamazepine in panic disorder.","volume":"146","author":"Tondo","year":"1989","journal-title":"Am J Psychiatry"},{"key":"R21-6-20210128","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1176\/ajp.145.9.1104","article-title":"Lack of efficacy of carbamazepine in the treatment of panic disorder.","volume":"145","author":"Uhde","year":"1988","journal-title":"Am J Psychiatry"},{"key":"R22-6-20210128","first-page":"122","article-title":"The EEG in obsessive-compulsive disorder.","volume":"45","author":"Jenike","year":"1984","journal-title":"J Clin Psychiatry"},{"key":"R23-6-20210128","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/0006-3223(87)90061-8","article-title":"Carbamazepine in obsessive-compulsive disorder.","volume":"22","author":"Joffe","year":"1987","journal-title":"Biol Psychiatry"},{"key":"R24-6-20210128","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/0269881103017002006","article-title":"Effects of gabapentin on anxiety induced by simulated public speaking.","volume":"17","author":"De Paris","year":"2003","journal-title":"J Psychopharmacol"},{"key":"R25-6-20210128","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00004714-199908000-00010","article-title":"Treatment of social phobia with gabapentin: a placebo-controlled study.","volume":"19","author":"Pande","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"R26-6-20210128","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/00004714-200008000-00011","article-title":"Placebo-controlled study of gabapentin treatment of panic disorder.","volume":"20","author":"Pande","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"R27-6-20210128","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/0269881105056526","article-title":"Levetiracetam in social phobia: a placebo controlled pilot study.","volume":"19","author":"Zhang","year":"2005","journal-title":"J Psychopharmacol"},{"key":"R28-6-20210128","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.4088\/JCP.v65n0909","article-title":"An open-label study of levetiracetam for the treatment of social anxiety disorder.","volume":"65","author":"Simon","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R29-6-20210128","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4088\/JCP.v67n0206","article-title":"Levetiracetam treatment-refractory posttraumatic stress disorder.","volume":"67","author":"Kinrys","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"R30-6-20210128","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/j.1440-1614.2000.0751c.x","article-title":"Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder.","volume":"34","author":"Kumar","year":"2000","journal-title":"Aust N Z J Psychiatry"},{"key":"R31-6-20210128","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S0006-3223(99)00011-6","article-title":"A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder.","volume":"45","author":"Hertzberg","year":"1999","journal-title":"Biol Psychiatry"},{"key":"R32-6-20210128","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1176\/appi.ajp.160.3.533","article-title":"Pregabalin in generalized anxiety disorder: a placebo-controlled trial.","volume":"160","author":"Pande","year":"2003","journal-title":"Am J Psychiatry"},{"key":"R33-6-20210128","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/01.jcp.0000084032.22282.ff","article-title":"A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder.","volume":"23","author":"Feltner","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"R34-6-20210128","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/archpsyc.62.9.1022","article-title":"Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.","volume":"62","author":"Rickels","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"R35-6-20210128","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/01.jcp.0000155820.74832.b0","article-title":"Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing.","volume":"25","author":"Pohl","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"R36-6-20210128","doi-asserted-by":"crossref","first-page":"771","DOI":"10.4088\/JCP.v67n0511","article-title":"Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine.","volume":"67","author":"Montgomery","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"R37-6-20210128","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/01.jcp.0000117423.05703.e7","article-title":"Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study.","volume":"24","author":"Pande","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"R38-6-20210128","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.4088\/JCP.v65n1120","article-title":"Treatment of posttraumatic stress disorder with phenytoin: an open-label pilot study.","volume":"65","author":"Bremner","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R39-6-20210128","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.4088\/JCP.v64n1016","article-title":"Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control.","volume":"64","author":"Rosenthal","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R40-6-20210128","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.4088\/JCP.v66n1109","article-title":"The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study.","volume":"66","author":"Pollack","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R41-6-20210128","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00213-005-0265-3","article-title":"Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment.","volume":"184","author":"Connor","year":"2006","journal-title":"Psychopharmacology"},{"key":"R42-6-20210128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4088\/JCP.v63n0104","article-title":"Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report.","volume":"63","author":"Berlant","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R43-6-20210128","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-244X-4-24","article-title":"Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder.","volume":"4","author":"Berlant","year":"2004","journal-title":"BMC Psychiatry"},{"key":"R44-6-20210128","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.4088\/JCP.v65n1213","article-title":"An open trial of topiramate in the treatment of generalized social phobia.","volume":"65","author":"Van Ameringen","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R45-6-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/da.20118","article-title":"Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series.","volume":"23","author":"Van Ameringen","year":"2006","journal-title":"Depress Anxiety"},{"key":"R46-6-20210128","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/01.jcp.0000220524.44905.9f","article-title":"The effects of topiramate adjunctive treatment added to antidepressants in patients with resistant obsessive-compulsive disorder.","volume":"26","author":"Rubio","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"R47-6-20210128","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/00004714-199604000-00013","article-title":"Vigabatrin and posttraumatic stress disorder.","volume":"16","author":"Macleod","year":"1996","journal-title":"J Clin Psychopharmacol"},{"key":"R48-6-20210128","first-page":"361","article-title":"Valproate in combat-related posttraumatic stress disorder.","volume":"52","author":"Fesler","year":"1991","journal-title":"J Clin Psychiatry"},{"key":"R49-6-20210128","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/00004714-200202000-00021","article-title":"Valproate therapy for chronic, combat-induced posttraumatic stress disorder.","volume":"22","author":"Petty","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"R50-6-20210128","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1023\/A:1024797014210","article-title":"Divalproex in posttraumatic stress disorder: an open-label clinical trial.","volume":"12","author":"Clark","year":"1999","journal-title":"J Trauma Stress"},{"key":"R51-6-20210128","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.jcp.0000106234.36344.a4","article-title":"Valproate monotherapy in the treatment of civilian patients with non-combat-related posttraumatic stress disorder: an open-label study.","volume":"24","author":"Otte","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"R52-6-20210128","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/070674379003500309","article-title":"Valproic acid and panic disorder.","volume":"35","author":"Primeau","year":"1990","journal-title":"Can J Psychiatry"},{"key":"R53-6-20210128","first-page":"134","article-title":"Panic disorder: treatment with valproate.","volume":"55","author":"Woodman","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"R54-6-20210128","first-page":"169","article-title":"Valproic acid for the treatment of social anxiety disorder.","volume":"18","author":"Kinrys","year":"2003","journal-title":"Int Clin Psychopharmacol"},{"key":"R55-6-20210128","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/milmed\/162.9.616","article-title":"Pharmacological management of post-traumatic stress disorder: clinical summary of a five-year retrospective study, 1990-1995.","volume":"162","author":"Viola","year":"1997","journal-title":"Mil Med"},{"key":"R56-6-20210128","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/10401239709147793","article-title":"Response of obsessive compulsive disorder to carbamazepine in two patients with comorbid epilepsy.","volume":"9","author":"Koopowitz","year":"1997","journal-title":"Ann Clin Psychiatry"},{"key":"R57-6-20210128","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4088\/JCP.v61n0712c","article-title":"Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder.","volume":"61","author":"Iwata","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"R58-6-20210128","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1177\/070674370204701014","article-title":"Oxcarbazepine treatment of posttraumatic stress disorder.","volume":"47","author":"Berigan","year":"2002","journal-title":"Can J Psychiatry"},{"key":"R59-6-20210128","doi-asserted-by":"crossref","first-page":"404","DOI":"10.4088\/JCP.v58n0906e","article-title":"Oxcarbazepine for panic disorder occurring after two grand mal seizures: a case report.","volume":"58","author":"Windhaber","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"R60-6-20210128","first-page":"316","article-title":"Successful treatment of obsessive compulsive disorder with oxcarbazepine. A case report.","volume":"98","author":"McMeekin","year":"2002","journal-title":"J S C Med Assoc"},{"key":"R62-6-20210128","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1176\/jnp.2.2.193","article-title":"Anticonvulsant-responsive panic attacks with temporal lobe EEG abnormalities.","volume":"2","author":"McNamara","year":"1990","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R63-6-20210128","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/0269881105048996","article-title":"Effects of phenytoin on memory, cognition and brain structure in post-traumatic stress disorder: a pilot study.","volume":"19","author":"Bremner","year":"2005","journal-title":"J Psychopharmacol"},{"key":"R64-6-20210128","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1176\/ajp.148.8.1086b","article-title":"Divalproex in posttraumatic stress disorder.","volume":"148","author":"Szymanski","year":"1991","journal-title":"Am J Psychiatry"},{"key":"R65-6-20210128","first-page":"500","article-title":"Valproate pretreatment for the difficult-to-treat patient with OCD.","volume":"55","author":"Deltito","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"R66-6-20210128","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4088\/JCP.v59n0207b","article-title":"Valproate monotherapy in an SRI-intolerant OCD patient.","volume":"59","author":"Cora-Locatelli","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"R67-6-20210128","first-page":"81","article-title":"Valproate treatment of comorbid panic disorder and affective disorders in two alcoholic patients.","volume":"14","author":"Brady","year":"1994","journal-title":"J Clin Psychopharmacol"},{"key":"R68-6-20210128","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1176\/ajp.151.10.1521a","article-title":"Treatment of panic disorder and comorbid substance abuse with divalproex sodium.","volume":"151","author":"Roberts","year":"1994","journal-title":"Am J Psychiatry"},{"key":"R69-6-20210128","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1176\/jnp.3.2.232-a","article-title":"Treatment of panic disorder and benzodiazepine withdrawal with valproate.","volume":"3","author":"McElroy","year":"1991","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R70-6-20210128","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1176\/ajp.153.6.842b","article-title":"Valproic acid for panic disorder associated with multiple sclerosis.","volume":"153","author":"Marazziti","year":"1996","journal-title":"Am J Psychiatry"},{"key":"R71-6-20210128","first-page":"78","article-title":"Sodium valproate and clonazepam for treatment-resistant panic disorder.","volume":"17","author":"Ontiveros","year":"1992","journal-title":"J Psychiatry Neurosci"},{"key":"R72-6-20210128","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00002826-200207000-00006","article-title":"Antiepileptic drugs in posttraumatic stress disorder.","volume":"25","author":"Iancu","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"R73-6-20210128","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0006-3223(93)90010-B","article-title":"Valproate treatment of panic disorder and lactate-induced panic attacks.","volume":"33","author":"Keck","year":"1993","journal-title":"Biol Psychiatry"},{"key":"R74-6-20210128","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/070674379804300109","article-title":"Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy.","volume":"43","author":"Baetz","year":"1998","journal-title":"Can J Psychiatry"},{"key":"R75-6-20210128","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1177\/026988110401800319","article-title":"Vigabatrin and tiagabine might have antipanic properties.","volume":"18","author":"Zwanzger","year":"2004","journal-title":"J Psychopharmacol"},{"key":"R76-6-20210128","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0893-133X(01)00266-4","article-title":"Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers.","volume":"25","author":"Zwanzger","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"R77-6-20210128","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/00004714-200110000-00017","article-title":"Anxiolytic effects of vigabatrin in panic disorder.","volume":"21","author":"Zwanzger","year":"2001","journal-title":"J Clin Psychopharmacol"},{"issue":"suppl 50","key":"R78-6-20210128","first-page":"450","article-title":"Antiepileptic drugs potentiating GABA.","author":"Meldrum","year":"1999","journal-title":"Electroencephalogr Clin Neurophysiol"},{"key":"R79-6-20210128","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4088\/JCP.v64n0215f","article-title":"AMPA blockade may be the mechanism underlying the efficacy of topiramate in PTSD.","volume":"64","author":"Zullino","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R80-6-20210128","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/da.10099","article-title":"Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers.","volume":"18","author":"Zwanzger","year":"2003","journal-title":"Depress Anxiety"},{"key":"R81-6-20210128","first-page":"53","article-title":"The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series.","volume":"36","author":"Schwartz","year":"2002","journal-title":"Psychopharmacol Bull"},{"key":"R82-6-20210128","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/da.10104","article-title":"Tiagabine for the treatment of anxiety.","volume":"18","author":"Crane","year":"2003","journal-title":"Depress Anxiety"},{"key":"R83-6-20210128","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1177\/070674370204700821","article-title":"Treatment of posttraumatic stress disorder with tiagabine.","volume":"47","author":"Berigan","year":"2002","journal-title":"Can J Psychiatry"},{"key":"R84-6-20210128","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.4088\/JCP.v64n1204","article-title":"Tiagabine for posttraumatic stress disorder: a case series of 7 women.","volume":"64","author":"Taylor","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R85-6-20210128","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1176\/ajp.155.7.992","article-title":"Gabapentin as a potential treatment for anxiety disorders.","volume":"155","author":"Pollack","year":"1998","journal-title":"Am J Psychiatry"},{"key":"R86-6-20210128","first-page":"84","article-title":"Gabapentin treatment for posttraumatic stress disorder.","volume":"45","author":"Brannon","year":"2000","journal-title":"Can J Psychiatry"},{"key":"R87-6-20210128","doi-asserted-by":"crossref","first-page":"480","DOI":"10.4088\/JCP.v59n0907d","article-title":"Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder.","volume":"59","author":"Cora-Locatelli","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"R88-6-20210128","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4088\/JCP.v59n0308a","article-title":"Rebound psychiatric and physical symptoms after gabapentin discontinuation.","volume":"59","author":"Cora-Locatelli","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"R89-6-20210128","first-page":"305","article-title":"Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders.","volume":"43","author":"Chouninard","year":"1998","journal-title":"Can J Psychiatry"},{"key":"R90-6-20210128","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3109\/10401230109148960","article-title":"Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy.","volume":"13","author":"Hamner","year":"2001","journal-title":"Ann Clin Psychiatry"},{"key":"R91-6-20210128","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R92-6-20210128","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2165\/00003495-200464190-00004","article-title":"Antiepileptic drugs in the treatment of anxiety disorders.","volume":"64","author":"Van Ameringen","year":"2004","journal-title":"Drugs"},{"key":"R93-6-20210128","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s11920-005-0079-3","article-title":"Anticonvulsants in anxiety disorders.","volume":"7","author":"Kinrys","year":"2005","journal-title":"Curr Psychiatry Rep"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/jcp.0b013e318059361a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T03:16:46Z","timestamp":1736997406000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-200706000-00006"}},"subtitle":["A Critical Review of the Evidence"],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":92,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e318059361a","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}